

PCRopsis™ Oral Rinse offers a simple means of collecting and transporting oral samples for direct PCR

MAIMI, FLORIDA, USA, October 10, 2022 /EINPresswire.com/ -- PCRopsis

LLC, a subsidiary of Entopsis Inc., launched PCRopsis™ <u>Oral Rinse</u>, a novel device for the collection and transport of oral samples with distinct advantages over alternative approaches.



PCRopsis™ Oral Rinse is the only such product that offers simple self collection, helps mediate in-transit nucleic acid extraction of bacteria and viruses, and is compatible with direct PCR."

Obdulio Piloto, Ph.D., CEO of Entopsis Inc.

Oral samples offer a simple, low cost, and user-friendly means of collecting oral samples for a variety of applications; such as, DNA sequencing, respiratory virus testing, oral cancer detection, toxicology, and many others. These samples can be conveniently collected at home and shipped to testing sites.

Key Advantages of PCRopsis™ Oral Rinse over Alternative Approaches:

1. Simple sample collection: safe ingredients allow for self collection of oral samples by swishing the liquid in your

mouth – no need for swabs, secondary inactivating reagents, careful mixing of saliva with reagents, or pipettes to transfer small volumes


- 2. Keeps RNA stable at room temperature up to 7 days, and over 70 days when samples are stored at 4°C or -20°C
- 3. Makes saliva samples easier to manipulate in the laboratory using pipettes thereby improving pipetting accuracy
- 4. Inactivates microorganisms found in the human mouth at room temperature
- 5. Helps mediate in-transit nucleic acid extraction of bacteria and viruses
- 6. Allows for direct PCR components do not inhibit reverse transcriptase or DNA polymerase

PCRopsis™ Oral Rinse is the result of a collaborative research and development effort between PCRopsis LLC, Protean Labs LLC, and Polarity Ventures LLC. This collaboration produced a best in class product, with a variety of unique capabilities for various applications.

About Entopsis Inc.
Entopsis was founded in 2011. It
partners, manufactures, and
commercializes a number of
proprietary platforms. The company
utilizes this distinct convergence of
technology to solve key scientific
problems, particularly for medical
diagnostics. Entopsis is predominantly
focused in the areas of oncology and
infectious diseases, and explores new
areas lacking suitable solutions. For
more information, please visit
www.Entopsis.com.



PCRopsis offers a number of direct PCR (extraction-free PCR) solutions for PCR testing of human samples. These



technologies streamline PCR-based testing, while decreasing costs. The company develops technologies in-house and establishes strategic partnerships to offer best in class products to research and clinical testing laboratories. For more information, please visit www.PCRopsis.com.

About Polarity Ventures LLC

Polarity Ventures is a research and development firm focused on point-of-care diagnostics, drug delivery, ophthalmology, microbial-based scaffolding, and longevity. The company partners with academicians, engineers, scientists, consultants, and entrepreneurs to identify and solve business opportunities. For more information, please visit www.Polarity-Ventures.com

About Protean Labs LLC

Protean Labs consists of a team of scientists with deep insights into nanotechnology and molecular biology. Over the past 10+ years, the company developed a broad portfolio of proprietary technologies. The research team leverages in-house assets to address scientific problems presented by partnering entities.

Obdulio Piloto Entopsis info@entopsis.com

This press release can be viewed online at: https://www.einpresswire.com/article/595206652 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 Newsmatics Inc. All Right Reserved.